The effect of fluticasone, budesonide and mometasone on nasal polyposis

Comparison of the effect Sprays of fluocycan, boutsonide and mometazone in patients with nasal-sinus polyposis after sinus endoscopic surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043934N7

Enrollment

Registered

2020-08-04

Start date

2020-06-30

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal polyps. Nasal polyp

Interventions

Intervention 1: Intervention group 1: Group A receiving fluticasone nasal spray twice a day, 0.1 mg (manufactured by Jaber Bin Hayan Pharmaceutical Company) for 4 weeks. Intervention 2: Intervention g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic rhinosinusitis with nasal polyps who have undergone sinus endoscopic surgery. Patients aged 15 to 70 years Having conscious satisfaction

Exclusion criteria

Exclusion criteria: Existence of eye disease Existence of known immunodeficiency disease Infectious symptoms include purulent discharge from the back of the throat and nose Having Allergic rhinitis

Design outcomes

Primary

Measure	Time frame
Runny nose. Timepoint: runny nose before and After treatment. Method of measurement: By asking the patient.;Headache. Timepoint: headache before and After treatment. Method of measurement: By asking the patient.;Nasal congestion before and After treatment. Timepoint: nasal congestion. Method of measurement: By asking the patient.;Sinus pain. Timepoint: sinus pain before and After treatment. Method of measurement: By asking the patient.;Pain around the eyes. Timepoint: pain around the eyes before and After treatment. Method of measurement: By asking the patient.;Pus in the nose. Timepoint: pus in the nose before and After treatment. Method of measurement: By asking the patient.;Cough. Timepoint: cough before and After treatment. Method of measurement: By asking the patient.;Decreased sense of smell Before and After Treatment. Timepoint: Decreased sense of Smell Before and After Treatment. Method of measurement: By Asking The Patient.	—

Measure

Time frame

Runny nose. Timepoint: runny nose before and After treatment. Method of measurement: By asking the patient.;Headache. Timepoint: headache before and After treatment. Method of measurement: By asking the patient.;Nasal congestion before and After treatment. Timepoint: nasal congestion. Method of measurement: By asking the patient.;Sinus pain. Timepoint: sinus pain before and After treatment. Method of measurement: By asking the patient.;Pain around the eyes. Timepoint: pain around the eyes before and After treatment. Method of measurement: By asking the patient.;Pus in the nose. Timepoint: pus in the nose before and After treatment. Method of measurement: By asking the patient.;Cough. Timepoint: cough before and After treatment. Method of measurement: By asking the patient.;Decreased sense of smell Before and After Treatment. Timepoint: Decreased sense of Smell Before and After Treatment. Method of measurement: By Asking The Patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZabihullah Mohaghegh

Birjand University of Medical Sciences

oabstudent@gmail.com+98 56 3232 3232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026